STELLA PHARMA CORPORATION [4888.T]
TOKYO, Mar 31 (Pulse News Wire) – Stella Pharma Corporation (4888.T) plans to issue shares and warrants across four rounds to raise up to ¥1 billion immediately through share issuance and potentially more via warrant exercise. The program includes ordinary share issuances totaling up to ¥696 per share, assuming the second to fourth issues align with March 30, 2026 closing prices.
Each warrant issuance will target exercise prices based on closing prices on various dates: the first at ¥1,000, the second at ¥1,050, the third at ¥1,100, and the fourth also at ¥1,100. The company chose this method over public offerings or debt financing due to potential dilution concerns and fixed repayment obligations associated with loans.
Instead, Stella Pharma seeks flexibility to support ongoing research and development, international expansion, and facility growth without immediate liquidity constraints. Exercise of the warrants could lead to additional funding of up to ¥1 billion, contingent upon market conditions and investor decisions.
Scheduled issuance dates are set for subsequent rounds: the second issuance decision on June 05, 2026, allocation on June 22, 2026; the third issuance decision on August 13, 2026, allocation on August 31, 2026; and the fourth issuance decision on October 19, 2026, allocation on November 04, 2026.
🟢 Confidence: High AI-translated content.